Results of conventional (myeloablative) allogeneic hematopoietic transplantation for CLL
| N . | Median age, y (range) . | Chemorefractory, % . | Donor, % related . | TCD, % . | NRM, % . | Grade II-IV aGVHD, % . | cGVHD, % . | Survival, % OS and/or PFS (y) . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|---|
| 54 | 41 (21-58) | 39 | 100 | 15 | 46 (3 y) | 37 | 49 (17 extensive) | 46 OS (3 y) | Michallet et al34 (1996) |
| 38 | 45 (26-57) | 55 (26 FR) | 0 | 5 | 38 (5 y) | 45 | 85 | 33 OS, 30 PFS (5 y) | Pavletic et al35 (2005) |
| 25 | 47 (29-55) | 0 | 100 | 100 | 24 (6 y) | 50 | 50 extensive | 55 OS, 24 PFS (6 y) | Gribben et al36 (2005) |
| 30 | 48 (32-59) | NS | 66 | 7 | 47 (5 y) | 52 | 65 | 39 OS, 39 PFS (5 y) | Toze et al37 (2005) |
| 12 | 39 (29-53) | NS | 100 | 66 | 25 | 25 | 40 | 65 OS, 65 PFS | Esteve et al38 (2001) |
| 28 | 43 (26-58) | 68 | 73 | 0 | 32 (6 y) | 49 | 64 | 45 OS, 42 PFS (5 y) | Khouri et al39 (2002) |
| N . | Median age, y (range) . | Chemorefractory, % . | Donor, % related . | TCD, % . | NRM, % . | Grade II-IV aGVHD, % . | cGVHD, % . | Survival, % OS and/or PFS (y) . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|---|
| 54 | 41 (21-58) | 39 | 100 | 15 | 46 (3 y) | 37 | 49 (17 extensive) | 46 OS (3 y) | Michallet et al34 (1996) |
| 38 | 45 (26-57) | 55 (26 FR) | 0 | 5 | 38 (5 y) | 45 | 85 | 33 OS, 30 PFS (5 y) | Pavletic et al35 (2005) |
| 25 | 47 (29-55) | 0 | 100 | 100 | 24 (6 y) | 50 | 50 extensive | 55 OS, 24 PFS (6 y) | Gribben et al36 (2005) |
| 30 | 48 (32-59) | NS | 66 | 7 | 47 (5 y) | 52 | 65 | 39 OS, 39 PFS (5 y) | Toze et al37 (2005) |
| 12 | 39 (29-53) | NS | 100 | 66 | 25 | 25 | 40 | 65 OS, 65 PFS | Esteve et al38 (2001) |
| 28 | 43 (26-58) | 68 | 73 | 0 | 32 (6 y) | 49 | 64 | 45 OS, 42 PFS (5 y) | Khouri et al39 (2002) |
TCD indicates T-cell depletion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; FR, fludarabine-refractory; and NS, not stated.